Pegylated-IFNα2a for HIV/hepatitis C virus coinfected patients: out with the old, in with the new

Bibliography

• Puoti M, Moioli MC, Travi G, et al. The burden of liver disease in human immunodeficiency virus-infected patients. Semin liver dis 2012;32(2):103-13
   PubMed Web of Science ®Google Scholar
• Davis GL, Albright JE, Cook SF, et al. Projecting future complications of chronic hepatitis C in the United States. Liver transpl 2003;9(4):331-8
   PubMed Web of Science ®Google Scholar
• HIV and AIDS in the United States by Geographic Distribution. CDC. Available from: http://www.cdc.gov/hiv/statistics/basics/geographicdistribution.html [Cited 5 July 2014]
   Google Scholar
• Smith C, Sabin CA, Lundgren JD, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010;24(10):1537-48
   PubMed Web of Science ®Google Scholar
• Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997;26(1):1-5
   PubMed Web of Science ®Google Scholar
• Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001;33(4):562-9
   PubMed Web of Science ®Google Scholar
• van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308(24):2584-93
   PubMed Web of Science ®Google Scholar
• Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007;147(10):677-84
   PubMed Web of Science ®Google Scholar
• Casado JL, Quereda C, Moreno A, et al. Regression of liver fibrosis is progressive after sustained virological response to HCV therapy in patients with hepatitis C and HIV coinfection. J Viral Hepat 2013;20(12):829-37
   PubMed Web of Science ®Google Scholar
• Limketkai BN, Mehta SH, Sutcliffe CG, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA 2012;308(4):370-8
   PubMed Web of Science ®Google Scholar
• Chung RT, Andersen J, Volberding P, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351(5):451-9
   PubMed Web of Science ®Google Scholar
• Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351(5):438-50
   PubMed Web of Science ®Google Scholar
• Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004;292(23):2839-48
   PubMed Web of Science ®Google Scholar
• Nunez M, Miralles C, Berdun MA, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 2007;23(8):972-82
   PubMed Web of Science ®Google Scholar
• Cotte L, Vincent C, Sogni P, et al. Telaprevir in treatment-experienced HIV-HCV G1 coinfected patients (ANRS HC26 TelapreVIH). 21st Conference on Retroviruses and Opportunistic Infections; 3 – 6 March 2014; Bosto, MA
   Google Scholar
• Dieterich DT, Rockstroh JK, Orkin C, et al. Simeprevir plus PegIFN/ribavirin in HCV genotype-1/HIV-1 co-infection (Study C212). 21st Conference on Retroviruses and Opportunistic Infections; 3 – 6 March 2014; Boston, MA
   Google Scholar
• Poizot-Martin I, Bellissant E, Colson P, et al. Boceprevir for previously treated HCV-HIV coinfected patients: the ANRS-HC27 BocepreVIH Trial. 21st Conference on Retroviruses and Opportunistic Infections; 3 – 6 March 2014; Boston, MA
   Google Scholar
• Recommmendations for testing, managing, and treating hepatitis C. 2014. Available from: http://www.hcvguidelines.org/fullreport [Cited 4 January 2014]
   Google Scholar
• EASL recommendations on treatment of hepatitis C. 2014. Available from: http://files.easl.eu/easl-recommendations-on-treatment-of-hepatitis-C/index.html-p=II [Cited 7 May 2014]
   Google Scholar
• European medicines agency - product information - Pegasys: EPAR. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000395/human_med_000974.jsp&mid=WC0b01ac058001d124
   Google Scholar
• Aghemo A, Rumi MG, Colombo M. Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C. Expert Rev Anti Infect Ther 2009;7(8):925-35
   PubMed Web of Science ®Google Scholar
• Bailon P, Palleroni A, Schaffer CA, et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 2001;12(2):195-202
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347(13):975-82
   PubMed Web of Science ®Google Scholar
• Glue P, Fang JW, Rouzier-Panis R, et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin pharmacol Ther 2000;68(5):556-67
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361(6):580-93
   PubMed Web of Science ®Google Scholar
• Flori N, Funakoshi N, Duny Y, et al. Pegylated interferon-alpha2a and ribavirin versus pegylated interferon-alpha2b and ribavirin in chronic hepatitis C: a meta-analysis. Drugs 2013;73(3):263-77
   PubMed Web of Science ®Google Scholar
• Berenguer J, Gonzalez-Garcia J, Lopez-Aldeguer J, et al. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. J Antimicrob Chemother 2009;63(6):1256-63
   PubMed Web of Science ®Google Scholar
• Laguno M, Cifuentes C, Murillas J, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 2009;49(1):22-31
   PubMed Web of Science ®Google Scholar
• Dieterich DT, Rodriguez-Torres M, Sulkowski MS, et al. In APRICOT and PARADIGM 99% of HIV-HCV co-infected patients with an SVR12 achieved an SVR24 validating SVR12 as an endpoint for trials in this population. H. The 63rd Annual Meeting of the American Association for the Study of Liver Diseases: the Liver Meeting 2012; Boston, MA; 2012. p. 587A-8A
   Google Scholar
• Ioannou GN, Scott JD, Yang Y, et al. Rates and predictors of response to anti-viral treatment for hepatitis C virus in HIV/HCV co-infection in a nationwide study of 619 patients. Aliment Pharmacol Ther 2013;38(11-12):1373-84
   PubMed Web of Science ®Google Scholar
• Carosi G, Bruno R, Cariti G, et al. OPERA: use of pegylated interferon plus ribavirin for treating hepatitis C/HIV co-infection in interferon-naive patients. Antivir Ther 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Buti M, Agarwal K, Horsmans Y, et al. Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C. Gastroenterology 2014;146(3):744-753.e3
   PubMed Web of Science ®Google Scholar
• Telaprevir package insert. Available from: http://pi.vrtx.com/files/uspi_telaprevir.pdf [Cited 7 December 2012, cited 2013 December 2013]
   Google Scholar
• Sulkowski MS, Sherman KE, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013;159(2):86-96
   PubMed Web of Science ®Google Scholar
• Martel-Laferriere V, Brinkley S, Bichoupan K, et al. Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection. HIV Med 2014;15(2):108-15
   PubMed Web of Science ®Google Scholar
• Genebat M, Vera F, Hernandez-Quero J, et al. Efficacy and tolerability after 24weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfected subjects. Antiviral Res 2014;104:59-61
   PubMed Web of Science ®Google Scholar
• Bichoupan K, Martel-Laferriere V, Sachs D, et al. Costs of telaprevir-based triple therapy including adverse event management at the Mount Sinai Medical Center, NY $189,000 per SVR. 64th Annual Meeting of the American Association for the Study of Liver Diseases; 1 – 5Nov 2013; Washington, DC
   Google Scholar
• Flamm SL, Lawitz E, Jacobson I, et al. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin Gastroenterol Hepatol 2013;11(1):81-7.e4. quiz e5
   PubMed Web of Science ®Google Scholar
• Manns M, Marcellin P, Poordad F, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014;146(7):1669-79.e3
   PubMed Web of Science ®Google Scholar
• Dieterich DT, Tural C, Nelson M, et al. Faldaprevir plus pegylated interferon alfa-2a/ribavirin in HIV/HCV coinfection: STARTVerso4. 21st Conference on Retroviruses and Opportunistic Infections; 3 – 6 March 2014; Boston, MA
   Google Scholar
• Rodriguez-Torres M, Rodriguez-Orgengo J, Gaggar A, et al. Sofosbuvir and Peginterferon Alfa-2a/Ribavirin for Treatment-Naïve Genotype 1-4 HCV-Infected Patients Who Are Coinfected With HIV. Infectious Disease Week; 2 – 6 October 2013; San Francisco
   Google Scholar
• Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368(20):1878-87
   PubMed Web of Science ®Google Scholar
• Jacobson I, Ghalib R, Rodriguez-Torres M, et al. SVR results of a once-daily regimen of simeprevir (SMV, TMC435) plus sofosbuvir (SOF, GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: The COSMOS study. 64rd Annual Meeting of the American Association for the Study of Liver Diseases; 1 – 5 November 2013; Washington, DC
   Google Scholar
• Osinusi A, Townsend K, Nelson A, et al. Use of sofosbuvir/ledipasvir fixed dose combination for treatment of hcv genotype-1 infection in patients coinfected with hiv. EASL - The International Liver Congress 2014 49th Annual Meeting of the European Association for the Study of the Liver; 9 – 13 April 2014; London, United Kingdom
   Google Scholar
• Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 2014;146(5):1176-92
   PubMed Web of Science ®Google Scholar